Cargando…

Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol

OBJECTIVE: This study evaluated the use of Corifollitropin alfa in patients with previous poor response to recombinant follicle stimulating hormone in long-term protocols using gonadotropin-releasing hormone. METHODS: Twenty-seven poor responders to previous treatment with the long term protocol usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salgueiro, Lister L., Rolim, Juliana R., Moura, Bernardo R. L., Machado, Suelen P. P., Haddad, Carolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Brazilian Society of Assisted Reproduction 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264376/ https://www.ncbi.nlm.nih.gov/pubmed/27584604 http://dx.doi.org/10.5935/1518-0557.20160028

Ejemplares similares

Corifollitropin alfa for poor responders patients, a prospective randomized study
por: Fusi, F. M., et al.
Publicado: (2020)

Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients
por: Selman, Helmy, et al.
Publicado: (2016)

Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles
por: Akarsu, Süleyman, et al.
Publicado: (2017)

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art
por: Carvalho, Bruno Ramalho de
Publicado: (2023)

The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist
por: Seyhan, Ayse, et al.
Publicado: (2011)

A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders
por: Wang, Huai-Ling, et al.
Publicado: (2016)

Low concentration of hyaluronidase for oocyte denudation can improve fertilization rates and embryo quality
por: de Moura, Bernardo R L, et al.
Publicado: (2017)

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol
por: Devroey, P., et al.
Publicado: (2009)

Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity
por: Norman, Robert J., et al.
Publicado: (2011)

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis
por: Fensore, Stefania, et al.
Publicado: (2015)

Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction
por: Park, Hyo Young, et al.
Publicado: (2015)

Association of progesterone production with serum anti-Müllerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa
por: Lee, Tsung-Hsien, et al.
Publicado: (2018)

Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35–42 years with a body weight ≥50 kg: a randomized controlled trial
por: Vuong, N L, et al.
Publicado: (2017)

An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism
por: Nieschlag, Eberhard, et al.
Publicado: (2017)

Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol
por: Griesinger, Georg, et al.
Publicado: (2016)

Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
por: Leader, Arthur, et al.
Publicado: (2013)

Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI
por: Khoa, Le Dang, et al.
Publicado: (2020)

Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders
por: Errázuriz, Joaquín, et al.
Publicado: (2019)

Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles
por: Oehninger, Sergio, et al.
Publicado: (2015)

Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study
por: Tsakiridis, Ioannis, et al.
Publicado: (2020)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot study
por: Decleer, W., et al.
Publicado: (2014)

Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction
por: Souza, Priscila Morais Galvão, et al.
Publicado: (2017)

Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial
por: Alvarado Franco, Carlos Alberto, et al.
Publicado: (2023)

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study
por: Barrenetxea, Gorka, et al.
Publicado: (2018)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol
por: Huang, Ting-Chi, et al.
Publicado: (2021)

Corifollitropin α followed by menotropin for poor ovarian responders’ trial (COMPORT): a protocol of a multicentre randomised trial
por: Polyzos, Nikolaos P, et al.
Publicado: (2013)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Corifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patientfriendly IVF
por: Decleer, W, et al.
Publicado: (2015)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
por: Manzi, Lucio, et al.
Publicado: (2022)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

Corifollitropin- [Formula: see text] compared to daily r-FSH in for patients undergoing intracytoplasmic sperm injection: Clinical trial study
por: Zahiri Sorouri, Ziba, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_46bkjjces01qtkcttrqnmtdtbk